This study presents a valuable finding on the mutational order for common alterations in colorectal cancer. The evidence of in vitro growth assays comparing mutations is solid, although inclusion of ...

When the performance of AI models was assessed within stratified patient subgroups, such as only high-grade breast cancers or ...

Late in 2025, we covered the development of an AI system called Evo that was trained on massive numbers of bacterial genomes. So many that, when prompted with sequences from a cluster of related genes ...

Tempus AI's diagnostics arm is surging in 2025 as precision oncology testing, MRD adoption, AI-driven genomic tools and the Ambry Genetics acquisition expand capabilities.

Scantox Group today announced it has acquired the nonclinical genomic safety business of TwinStrand Biosciences, Inc. through a technology transfer and license agreement. Under the agreement, Scantox ...

Researchers warn malicious packages can harvest secrets, weaponize CI systems, and spread across projects while carrying a ...

The day we discovered that our then 15-month-old baby was one of just 200 people in the world with a genetic brain condition will be for ever etched on my mind.

Morgan Stanley Technology, Media & Telecom Conference 2026 March 3, 2026 12:15 PM ESTCompany ParticipantsEric Lefkofsky ...

Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating ...

Cash Burn -- $50.2 million in 2025, an improvement from $57.8 million in 2024 due to lower headcount and development costs.

By Hugo Francisco de Souza Rare genetic variants in a little-studied nicotine receptor subunit are linked to markedly lower ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript February 26, 2026 Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.14 ...